Eli Lilly & Co., the maker of the blockbuster Mounjaro diabetes drug, plans to invest more than $1 billion for contract manufacturing in India, amid 100% US tariff on the pharma sector. Eli Lilly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback